133 related articles for article (PubMed ID: 24977434)
1. Acceptable mismatching at the class II epitope level: the Canadian experience.
Wiebe C; Nickerson P
Curr Opin Organ Transplant; 2014 Aug; 19(4):442-6. PubMed ID: 24977434
[TBL] [Abstract][Full Text] [Related]
2. Terasaki Epitope Mismatch Burden Predicts the Development of De Novo DQ Donor-Specific Antibodies and are Associated With Adverse Allograft Outcomes.
Willicombe M; Blow M; Santos-Nunez E; Freeman C; Brookes P; Taube D
Transplantation; 2018 Jan; 102(1):127-134. PubMed ID: 28731902
[TBL] [Abstract][Full Text] [Related]
3. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
[TBL] [Abstract][Full Text] [Related]
4. Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation.
Kubal CA; Mangus R; Ekser B; Mihaylov P; Ceballos B; Higgins N; Chalasani N; Ghabril M; Nephew L; Lobashevsky A
Liver Transpl; 2018 Aug; 24(8):1101-1108. PubMed ID: 30142248
[TBL] [Abstract][Full Text] [Related]
5. Class II HLA Eplet Mismatch Is a Risk Factor for De Novo Donor-Specific Antibody Development and Antibody-mediated Rejection in Kidney Transplantation Recipients.
Kishikawa H; Kinoshita T; Hashimoto M; Fukae S; Taniguchi A; Yamanaka K; Nakagawa M; Nishimura K
Transplant Proc; 2018 Oct; 50(8):2388-2391. PubMed ID: 30316363
[TBL] [Abstract][Full Text] [Related]
6. Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression.
Snanoudj R; Kamar N; Cassuto E; Caillard S; Metzger M; Merville P; Thierry A; Jollet I; Grimbert P; Anglicheau D; Hazzan M; Choukroun G; Hurault De Ligny B; Janbon B; Vuiblet V; Devys A; Le Meur Y; Delahousse M; Morelon E; Bailly E; Girerd S; Amokrane K; Legendre C; Hertig A; Rondeau E; Taupin JL
Kidney Int; 2019 Jun; 95(6):1471-1485. PubMed ID: 30955869
[TBL] [Abstract][Full Text] [Related]
7. Association between PIRCHE-II scores and de novo allosensitization after reduction of immunosuppression during SARS-CoV-2 infection in kidney transplant recipients.
Castrezana-Lopez K; Malchow R; Nilsson J; Kokkonen SM; Rho E; von Moos S; Mueller TF; Schachtner T
Transpl Infect Dis; 2023 Apr; 25(2):e14052. PubMed ID: 36884207
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
[TBL] [Abstract][Full Text] [Related]
9. HLA molecular epitope mismatching and long-term graft loss in pediatric heart transplant recipients.
Sullivan PM; Warner P; Kemna MS; Albers EL; Law SP; Weiss NS; Law YM
J Heart Lung Transplant; 2015 Jul; 34(7):950-7. PubMed ID: 25727771
[TBL] [Abstract][Full Text] [Related]
10. Major histocompatibility complex class I-related chain A allele mismatching, antibodies, and rejection in renal transplantation.
Cox ST; Stephens HA; Fernando R; Karasu A; Harber M; Howie AJ; Powis S; Zou Y; Stastny P; Madrigal JA; Little AM
Hum Immunol; 2011 Oct; 72(10):827-34. PubMed ID: 21664940
[TBL] [Abstract][Full Text] [Related]
11. Effect of amino acid mismatch in the UNOS dataset.
Sasaki N; El-Awar N; Idica A
Clin Transpl; 2011; ():299-309. PubMed ID: 22755423
[TBL] [Abstract][Full Text] [Related]
12. Strategic Use of Epitope Matching to Improve Outcomes.
Wiebe C; Nickerson P
Transplantation; 2016 Oct; 100(10):2048-52. PubMed ID: 27362311
[TBL] [Abstract][Full Text] [Related]
13. The Synergistic Effect of Class II HLA Epitope-Mismatch and Nonadherence on Acute Rejection and Graft Survival.
Wiebe C; Nevins TE; Robiner WN; Thomas W; Matas AJ; Nickerson PW
Am J Transplant; 2015 Aug; 15(8):2197-202. PubMed ID: 26095765
[TBL] [Abstract][Full Text] [Related]
14. Donor selection in pediatric kidney transplantation using DR and DQ eplet mismatching: A new histocompatibility paradigm.
Bryan CF; Chadha V; Warady BA
Pediatr Transplant; 2016 Nov; 20(7):926-930. PubMed ID: 27448994
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
[TBL] [Abstract][Full Text] [Related]
16. How the definition of acceptable antigens and epitope analysis can facilitate transplantation of highly sensitized patients with excellent long-term graft survival.
Heidt S; Haasnoot GW; Claas FHJ
Curr Opin Organ Transplant; 2018 Aug; 23(4):493-499. PubMed ID: 29846197
[TBL] [Abstract][Full Text] [Related]
17. Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival.
Guidicelli G; Guerville F; Lepreux S; Wiebe C; Thaunat O; Dubois V; Visentin J; Bachelet T; Morelon E; Nickerson P; Merville P; Taupin JL; Couzi L
J Am Soc Nephrol; 2016 Feb; 27(2):615-25. PubMed ID: 26047793
[TBL] [Abstract][Full Text] [Related]
18. The quest to decipher HLA immunogenicity: Telling friend from foe.
Tambur AR; McDowell H; Hod-Dvorai R; Abundis MAC; Pinelli DF
Am J Transplant; 2019 Oct; 19(10):2910-2925. PubMed ID: 31165546
[TBL] [Abstract][Full Text] [Related]
19. Donor Specific Antibodies are not only directed against HLA-DR: Minding your Ps and Qs.
Cross AR; Lion J; Loiseau P; Charron D; Taupin JL; Glotz D; Mooney N
Hum Immunol; 2016 Nov; 77(11):1092-1100. PubMed ID: 27060781
[TBL] [Abstract][Full Text] [Related]
20. Epitope analysis of HLA-DQ antigens: what does the antibody see?
Tambur AR; Rosati J; Roitberg S; Glotz D; Friedewald JJ; Leventhal JR
Transplantation; 2014 Jul; 98(2):157-66. PubMed ID: 25003284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
